abstract |
The present invention derives from the identification of 26 gene transcripts (Markers) that exhibit aberrant expression levels in prostate disorder tissues. The invention therefore relates to diagnostic techniques for the detection of human prostate disorders, such as cancer, by detecting one or more of these Markers, intermediates, precursors or products (mRNA, cDNA, genomic DNA, or protein). The invention is also directed to methods for identifying modulators of prostate disorders, which modulators, such as chemical compounds, antisense molecules and antibodies interact with and modulate any one of the Markers identified. |